Company Update (NYSE:LLY): Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis

[PR Newswire] – INDIANAPOLIS, March 4, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically meaningful improvements … Read more on this. Eli Lilly and Company (LLY) , currently valued at $77.94B, started trading this morning at $73.37. Today, shares have traded between $72.90 and $74.06 per share with its 52-week range being $68.31 to $92.85. LLY shares are currently priced at 20.69x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -3.60x earnings multiple for the same period. And for passive income investors, the company pays shareholders $2.04 per share annually in dividends, yielding 2.80%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $0.84 per share, which would be $0.03 worse than the year-ago quarter and a $0.02 sequential decrease. Investors should also note that the full-year EPS estimate of $3.54 is a $0.11 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $4.83 Billion. If realized, that would be a 4.09% increase over the year-ago quarter. In terms of ratings, BMO Capital Markets upgraded LLY from Market Perform to Outperform (Nov 13, 2015). Previously, Credit Suisse upgraded LLY from Neutral to Outperform. Investors should keep in mind is that the average price target is $98.10, which is 33.71% above where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Market Update (NYSE:LLY): Lilly to Present Phase 3 Data at the American Academy of Dermatology (AAD) Annual Meeting for Ixekizumab in Psoriasis and Psoriatic Arthritis Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis Company Update (NYSE:LLY): US stocks are little changed in early trading after big week